证券记录 · 已归档季度
SNDX
Syndax Pharmaceuticals, Inc. · Healthcare · Biotechnology
20被追踪持有人
+1Δ持有人
39.69M持有股份
$610.59M报告持仓市值
+1新建仓位
−0清仓
动量输入（同类管理人）：
持有人广度 +5.3% ·
股份流向 +8.0% ·
净新建仓位 +5.0%
· 公式
广泛增持：持股数量上升，持有人数量增加
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q3 2025
持股变化趋势
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 62.74K | $1.14M | n/a | n/a |
| Q2 2026 | 94 | 0 | 57.51M | $1.26B | +9 | −9 |
| Q1 2026 | 97 | +6 | 52.14M | $1.22B | +10 | −4 |
| Q4 2025 | 91 | -3 | 57.71M | $1.21B | n/a | −3 |
| Q3 2025 | 20 | +1 | 39.69M | $610.59M | +1 | n/a |
| Q2 2025 | 16 | +1 | 29.55M | $276.77M | +1 | n/a |
| Q1 2025 | 12 | -1 | 16.71M | $205.25M | n/a | −1 |
| Q4 2024 | 13 | +1 | 16.01M | $211.65M | +1 | n/a |
| Q3 2024 | 11 | -1 | 14.02M | $269.82M | n/a | −1 |
| Q2 2024 | 12 | n/a | 17.35M | $356.12M | n/a | n/a |
持有人 · Q3 2025
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (被动) | 8.63M | -17.5% | $132.70M | 0.0% | ▼ Trim | 2 | SEC ↗ ×15 |
| 2 | Goldman Sachs Group ✦ | 5.49M | n/a | $84.41M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 3 | The Vanguard Group ✦ (被动) | 5.14M | +2.1% | $79.06M | 0.0% | ▲ Add | 2 | SEC ↗ ×5 |
| 4 | Point72 Asset Management ✦ | 4.26M | +100.0% | $65.46M | 0.2% | ▲ Add | 6 | SEC ↗ |
| 5 | State Street Global Advisors ✦ (被动) | 3.85M | +11.9% | $59.29M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 6 | Adage Capital Partners ✦ | 3.31M | +131.2% | $50.95M | 0.1% | ▲ Add | 6 | SEC ↗ |
| 7 | Geode Capital Management ✦ (被动) | 2.09M | +2.0% | $32.18M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 8 | Morgan Stanley ✦ | 1.20M | n/a | $18.45M | 0.0% | n/c | 1 | SEC ↗ ×8 |
| 9 | D. E. Shaw & Co. ✦ | 1.08M | +67.2% | $16.58M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 10 | Millennium Management ✦ | 1.05M | -34.5% | $16.10M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 11 | Renaissance Technologies ✦ | 860.50K | +2.7% | $13.24M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 12 | Two Sigma Investments ✦ | 712.66K | +27.9% | $10.96M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 13 | AQR Capital Management ✦ | 558.08K | +142.0% | $8.59M | 0.0% | ▲ Add | 6 | SEC ↗ ×5 |
| 14 | Citadel Advisors ✦ | 546.27K | -14.7% | $8.40M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 15 | JPMorgan Chase ✦ | 507.70K | n/a | $7.81M | 0.0% | n/c | 1 | SEC ↗ ×8 |
| 16 | Marshall Wace ✦ | 233.97K | +0.8% | $3.60M | 0.0% | ▲ Add | 2 | SEC ↗ ×3 |
| 17 | T. Rowe Price ✦ | 91.13K | +20.9% | $1.40M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 18 | Gotham Asset Management ✦ | 48.25K | 新增 | $742,265 | 0.0% | New | 1 | SEC ↗ |
| 19 | Wellington Management ✦ | 38.23K | +12.2% | $588,107 | 0.0% | ▲ Add | 6 | SEC ↗ ×4 |
| 20 | Fidelity (FMR) ✦ | 5.10K | -96.8% | $78,477 | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
"持仓权重"指该仓位占该管理人13F申报股票组合市值的比例，即持仓信心指标。✦ = 精选管理人。
新增买入方
| Gotham Asset Management | $742,265 | 0.0% |
已清仓
| 本季度无被追踪的退出仓位。 |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 244 持有人, 99.11M 股份, $2.29B 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
常见共同持仓
持有该证券的受追踪机构最常同时持有的其他证券：基于共同持有计数，而非基本面关联。
数据来源: 持股数据来源于已解析的13F普通股持仓（被追踪范围，变动对比集）；内部人行为来自Form 3/4/5；重大持股来自Schedule 13D/13G；所有文件均链接至SEC EDGAR原始申报。
报告期: Q3 2025 ·
方法论 ·
通过API获取此数据